TWGL 20/20 Global Inc

Emotional Intelligence Ventures and Mycotopia enter a Definitive Agreement on $382M merger transaction

Emotional Intelligence Ventures and Mycotopia enter a Definitive Agreement on $382M merger transaction

Entities on track to merge under PSLY.com and list on NASDAQ Stock Exchange

MIAMI and MAUI, Hawaii, May 19, 2022 (GLOBE NEWSWIRE) -- Mycotopia Therapies Inc. (OTC Pink: TPIA) (the “Company”), a biopharma company focused on research, technology, and the development of medical psychedelics, announced today an update on the previously announced merger with Ei.Ventures Inc. (“Ei”).

MERGER UPDATE

Ei has executed a definitive agreement with Mycotopia bringing the two entities together under PSLY.com as the companies move forward with their plan of uplisting to the NASDAQ stock exchange.

PSLY.com will be the parent entity owning all the assets of Ei and Mycotopia.

As previously reported, Ei shareholders will receive shares in PSLY.com based upon a valuation of $360 Million (subject to adjustment as set forth in the merger agreement) at the close of transaction. Mycotopia shareholders will receive shares in PSLY.com based upon a valuation of more than $23 million at the close of the transaction.

The companies anticipate closing the transaction on or about July 30, 2022.

MERGER SYNERGIES

Upon the closing of the transaction, PSLY.com will have a market value of approximately $383 million.

As Ei founder and CEO David Nikzad explains: “Of all the companies out there, we were most excited by Mycotopia. The areas where they specialize and have been working complement the Ei mission and business plan perfectly. They are helping us bring our products from the land back to the land. A journey my cofounder Jason Hobson and I began over 20 years ago. In Hawaii, we call this ‘going back to aina.’”

Since psilocybin is legal in Jamaica and the Netherlands, Ei will be able to leverage Mycotopia’s presence in both countries as a launching pad for its psilocybin consumer and medicinal product lines. This includes Odyssey Elixir, Psilly patches, and the Mana nutraceuticals line as well as any products developed in the future. Mycotopia will be able to leverage Ei’s proprietary formulations, as well as the benefits from the recent strategic investments in Odyssey Wellness LLC Elixir and Avicanna.

Mycotopia founder and CEO Ben Kaplan stated: “The combination of Ei and Mycotopia is a perfect combination of synergies. We are in markets where psilocybin is already legal. And Ei has been at the forefront of psychedelic thought, formulation, and implementation since the early days. Combining forces makes sense for the shareholders of both companies, as well as the millions of people that could potentially benefit from our combined product pipeline.”

PSLY.com will continue to expand in physical markets as well as in the digital realm – building on Ei’s recent purchase of hundreds of acres in the Metaverse. Combining the physical and digital will help Ei achieve its founding mission statement: to help over one billion people with natural, non-synthetic remedies derived from nature – not a lab.

Ei and Mycotopia will continue to update shareholders and the market on the path to a NASDAQ listing, as well as other material updates as PSLY.com launches into the market.

About Ei.Ventures Inc.:

Ei.Ventures Inc. is an early-stage tech company empowering mental wellness through psychoactive compounds, nutraceuticals and technology. Ei is leveraging blockchain, emerging technologies and the Metaverse to deliver governmental approved therapeutic treatment options that address the current global mental healthcare pandemic. It is the goal of Ei to utilize the development of these technologies, to create a safe, efficient, and secure way to provide telehealth services in general and specifically to the psychoactive therapeutics. Additional information on Ei can be found on the Ei’s website at: .

About Mycotopia Therapies

Mycotopia Therapies focuses on helping you heal and reclaim your life. Your journey of healing is an understanding of the causes and works to mental wellness through psychedelic enhanced psychotherapy, integrated with a professional team of mental wellness practitioners and cutting-edge technology. Psychedelic therapy is a holistic and spiritual approach providing healing and has shown successful treatment for many years. Additional information on Mycotopia Therapies can be found on the Company’s website at:   

Forward-Looking Statement Disclaimer

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading "Risk Factors" in 20/20 Global, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC's website,

Contact for Mycotopia Therapies

For Media and Investor Relations, please contact:

David L. Kugelman

(866) 692-6847 Toll Free - U.S. & Canada

(404) 281-8556 Mobile and WhatsApp

Email: Skype: kugsusa 

 



EN
19/05/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on 20/20 Global Inc

 PRESS RELEASE

Emotional Intelligence Ventures and Mycotopia enter a Definitive Agree...

Emotional Intelligence Ventures and Mycotopia enter a Definitive Agreement on $382M merger transaction Entities on track to merge under PSLY.com and list on NASDAQ Stock Exchange MIAMI and MAUI, Hawaii, May 19, 2022 (GLOBE NEWSWIRE) -- Mycotopia Therapies Inc. (OTC Pink: TPIA) (the “Company”), a biopharma company focused on research, technology, and the development of medical psychedelics, announced today an update on the previously announced merger with Ei.Ventures Inc. (“Ei”). MERGER UPDATE Ei has executed a definitive agreement with Mycotopia bringing the two entities together unde...

 PRESS RELEASE

Mycotopia Therapies Inc. Update on Ei.Ventures and Strategic Investmen...

Mycotopia Therapies Inc. Update on Ei.Ventures and Strategic Investments MIAMI, May 09, 2022 (GLOBE NEWSWIRE) -- Mycotopia Therapies Inc. (OTC Pink: TPIA), a biopharma company focused on research, technology, and the development of medical psychedelics, and Ei.Ventures Inc., a technology company empowering mental wellness through psychoactive compounds, nutraceuticals and web 3.0, are pleased to announce several strategic investments to advance the combined company's business plan. Ei.Ventures completed its Regulation A+ financing round on March 22, 2022 after announcing plans to go publi...

 PRESS RELEASE

Mycotopia Therapies Partners with Public Policy Specialist Psychedelic...

Mycotopia Therapies Partners with Public Policy Specialist PsychedelicsEUROPE to Explore Opportunities in the European Market Driving factors for growth in the European psychedelics market include growing acceptance of psychedelic medicine for treating depression and increasing prevalence of depression and mental disorders MIAMI, May 02, 2022 (GLOBE NEWSWIRE) -- (OTC Pink: TPIA) (the “Company”), a biopharma company focused on research, technology, and the development of medical psychedelics, announced today a partnership with Brussels-based . Mycotopia Therapies will collaborate with P...

 PRESS RELEASE

Mycotopia Therapies Inc. To Enter $13 Billion Medicinal Mushroom Marke...

Mycotopia Therapies Inc. To Enter $13 Billion Medicinal Mushroom Market With HAVN Life Sciences' Biopharmaceuticals And Ei.Ventures MANA Products Mycotopia Therapies and Ei.Ventures are moving forward with plans to form PSLY.COM; HAVN Life Sciences' functional mushrooms will be used in PSLY.COM’s MANA products, its line of whole-plant based medicinal mushroom nutraceuticals being developed for the consumer market MIAMI, March 21, 2022 (GLOBE NEWSWIRE) -- (OTC Pink: TPIA) (the “Company”), a biopharma company focused on research, technology, and the development of medical psychedelics, a...

 PRESS RELEASE

Mycotopia Therapies, Inc. Expands Presence In The Registered Mushroom ...

Mycotopia Therapies, Inc. Expands Presence In The Registered Mushroom Sector With HAVN Life Sciences Inc. Mycotopia Therapies plans to distribute HAVN’s line of natural OTC health products currently being registered with the Jamaican Ministry of Health MIAMI, March 17, 2022 (GLOBE NEWSWIRE) -- (OTC Pink: TPIA) (the “Company”), a biopharma company focused on research, technology, and the development of medical psychedelics, announced today plans to expand its supply agreement with (CSE: HAVN) (OTC Pink: HAVLF) to include functional mushrooms, which refers specifically to varieties of m...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch